Bataille R, Harousseau JL.
Multiple myeloma. N Engl J Med. 1997; 336:1657.-64 PubMedCrossRef
Mahendra P, Hood IM, Johnson D, Ethell M, Jestice HK, Scott MA, et al..
Autografting for multiple myeloma: a 5-year experience at a single institution. Bone Marrow Transplant. 1995; 16:759.-63 PubMed
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al..
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996; 335:91.-7 PubMed
Fermand JP, Ravaud P, Katsahian S, Divine M, Leblond V, Belanger C, et al.. High dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55 to 65 years of age [Abstract]. Blood. 1999; 94:Suppl 1396a.
Browman GP, Levine MN, Mohide EA, Hayward RS, Pritchard KI, Gafni A, et al..
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol. 1995; 13:502.-12 PubMed
Gregory WM, Richards MA, Malpas JS.
Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol. 1992; 10:334.-42 PubMed
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 1998; 16:3832.-42 PubMed
Myeloma Trialists' Collaborative Group (MTCG), Wheatley K. The role of interferon (IFN) as therapy for multiple myeloma: an overview of 24 randomized trials with over 4000 patients [Abstract]. Proc Annu Meet Am Soc Clin Oncol. 1998; 17:8a.
Trippoli S, Becagli P, Messori A, Tendi E. Maintenance treatment with interferon in multiple myeloma. A survival meta-analysis. Clin Drug Invest. 1997; 14:392.-9
Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al..
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997; 89:789.-93 PubMed
Musto P, Arena GD, Falcone A, Bodenizza Greco, MM Matera R, et al.. Intensive chemotherapy followed by single or multiple peripheral blood stem cell transplant (PBSCT) improves the prognosis of patients affected by multiple myeloma (MM) with high proliferative activity [Abstract]. Blood. 1999; 94:576a.
Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al..
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood. 2000; 95:7.-11 PubMed
Trippoli S, Messori A, Becagli P, Alterini R, Tendi E.
Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation. Oncol Rep. 1998; 5:1475.-82 PubMed
Björkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al..
Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996; 88:4711.-8 PubMed
Varterasian M, Janakiraman N, Karanes C, Abella E, Uberti J, Dragovic J, et al..
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant. Am J Clin Oncol. 1997; 20:462.-6 PubMed
Couban S, Stewart AK, Loach D, Panzarella T, Meharchand J.
Autologous and allogeneic transplantation for multiple myeloma at a single centre. Bone Marrow Transplant. 1997; 19:783.-9 PubMed
Harousseau JL, Attal M, Payen C, Facon T, Michaux JL, Guilhot F, et al.. Bone marrow (BM) versus peripheral blood versus CD34+progenitors as the source of stem cell for autologous transplantation in multiple myeloma [Abstract]. Blood. 1998; 92:443a.
Stewart AK, Schiller G, Vescio R, Ballester O, Noga S, Rugo H, et al.. CD34 selection does not prolong disease free or overall survival in myeloma patients undergoing autologous stem cell transplant: results of a phase III study [Abstract]. Blood. 1999; 94:714a.
Harrousseau JL, Facon T, Moreau P, Michallet M, Guilhot F, Hulin C, et al.. Comparison of high-dose melphalan 140 mg/m2 plus total body irradiation and high-dose melphalan 200mg/m2 as conditioning regimen for peripheral blood progenitor cell autotransplantation in patients with newly diagnosed multiple myeloma. Preliminary results of the IFM 9502 randomized trial [Abstract]. Blood. 1999; 94:713a.
Attal M, Harousseau JL, Facon T, Michaux JL, Guilhot F, Fruchard C, et al.. Single versus double transplant in myeloma: a randomized trial of the “Inter Group FranHais du Myelome” (IFM) [Abstract]. Blood. 1999; 94:714a.
Tosi P, Cavo M, Zamagni E, Ronconi S, Benni M, Tura S, et al.. A multi-centric randomized clinical trial comparing single versus double autologous peripheral blood stem cell transplantation for patients with newly diagnosed multiple myeloma: results of an interim analysis [Abstract]. Blood. 1999; 94:715a.
Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al..
A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol. 1998; 102:495.-502 PubMed
Harousseau JL, Attal M, Divine M, Milpied N, Marit G, Leblond V, et al..
Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transplant. 1995; 15:963.-9 PubMed
Raje N, Powles R, Horton C, Millar B, Shepherd V, Middleton G, et al..
Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma. Br J Cancer. 1997; 75:1684.-9 PubMed
Larsson K, Björkstrand B, Ljungman P.
Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation. Support Care Cancer. 1998; 6:378.-83 PubMed
Björkstrand BT, Svensson H, Goldschmidt H, Ljungman PT, Apperley J, Remes K, et al.. 5489 autotransplants in multiple myeloma—a registry study from the European Group for Blood and Marrow Transplantation (EBMT) [Abstract]. Blood. 1999; 94:714a.
Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, et al..
Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood. 1995; 85:588.-96 PubMed
Prince HM, Imrie K, Sutherland DR, Keating A, Meharchand J, Crump RM, et al..
Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol. 1996; 93:142.-5 PubMed
Duncan N, Hewetson M, Powles R, Raje N, Mehta J.
An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant. 1996; 18:1175.-8 PubMed
Powles R, Raje N, Horton C, Mehta J, Singhal S, Hickish T, et al..
Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy. Leuk Lymphoma. 1996; 21:421.-7 PubMed
Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al..
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998; 92:3131.-6 PubMed
Palumbo A, Triolo S, Argentino C, Bringhen S, Dominietto A, Rus C, et al..
Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood. 1999; 94:1248.-53 PubMed
Mainwaring PN, Horton C, Powles R, Treleaven J. Role of autologous transplantation in patients with multiple myeloma (MM) aged 65 years and over [Abstract]. Blood. 1998; 92:662a.
Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, et al..
Age is not a prognostic variable with autotransplants for multiple myeloma. Blood. 1999; 93:51.-4 PubMed
Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Bhagwati N, et al.. High-dose chemotherapy and autologous transplantation in myeloma patients aged 65 years and over: a case–control comparison with younger patients [Abstract]. Blood. 1999; 94:578a.
Badros A, Zangari M, Desikan R, Anaissie E, Munshi N, Chatta G, et al.. Feasibility and efficacy of melphalan-based high-dose therapy (MEL-HDT) with autologous peripheral blood stem cell support for patients with multiple myeloma (MM) aged > =70 years [Abstract]. Blood. 1999; 94:578a.
Mehta J, Ayers D, Mattox S, Singh J, Singhal S, Siegel D, et al.. High-dose melphalan and autotransplantation in myeloma with renal impairment: A matched-pair comparison with patients without renal failure [Abstract]. Blood. 1997; 90:419a.
Vesole DH, Jagannath S, Tricot G, Vaught L, Bartogie B. High-dose intensive therapy with autologous transplantation (AT) in multiple myeloma (MM) patients over age 60 [Abstract]. Proc Annu Meet Am Soc Clin Oncol. 1994; 13:410.
Siegel DS, Jagannath S, Desikan KR, Tricot G, Bracy D, Maddox S, et al.. Feasibility of high-dose chemotherapy with peripheral blood stem cell support for multiple myeloma patients over the age 70 [Abstract]. Blood. 1996; 88:130a.
Durie BG, Salmon SE.
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36:842.-54 PubMed
Haas R, Möhle R, Frühauf S, Goldschmidt H, Witt B, Flentje M, et al..
Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 1994; 83:3787.-94 PubMed
Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F, et al..
Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med. 1997; 126:600.-7 PubMed
Henry JM, Sykes PJ, Brisco MJ, To LB, Juttner CA, Morley AA.
Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests. Br J Haematol. 1996; 92:614.-9 PubMed
Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood. 2002 Feb 1; 99(3):731-5. [PMID: 11806971]